Last reviewed · How we verify
Atropine Sulfate 01
Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.
Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity. Used for Anticholinergic toxicity and organophosphate poisoning, Bradycardia and heart block, Preoperative medication in anesthesia.
At a glance
| Generic name | Atropine Sulfate 01 |
|---|---|
| Also known as | LPTAT01 |
| Sponsor | LitePharmTech Co., Ltd. |
| Drug class | Anticholinergic agent / Muscarinic antagonist |
| Target | Muscarinic acetylcholine receptors (M1-M5) |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine, Anesthesia, Ophthalmology, Toxicology |
| Phase | Phase 3 |
Mechanism of action
Atropine competitively antagonizes acetylcholine at muscarinic receptors throughout the body, reducing parasympathetic effects on the heart, smooth muscle, and secretory glands. This results in increased heart rate, bronchodilation, reduced secretions, and mydriasis. It is commonly used to counteract cholinergic toxicity, manage bradycardia, and as an adjunct in anesthesia.
Approved indications
- Anticholinergic toxicity and organophosphate poisoning
- Bradycardia and heart block
- Preoperative medication in anesthesia
- Mydriasis for ophthalmic procedures
Common side effects
- Dry mouth
- Tachycardia
- Mydriasis and cycloplegia
- Urinary retention
- Hyperthermia
- Confusion or agitation
Key clinical trials
- Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine. (PHASE1)
- Study of Atropine Therapeutic Effect on Myopic Progression (PHASE3)
- The Pathophysiology of Orthostatic Hypotension (PHASE1)
- Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population
- Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atropine Sulfate 01 CI brief — competitive landscape report
- Atropine Sulfate 01 updates RSS · CI watch RSS
- LitePharmTech Co., Ltd. portfolio CI